AllDocs -> cancers

Page 2 Mortality trends in England; ICD9 (204), ICD10 (C91); File: Sepho 96-04 V2 Lymphoid leukaemia in England 1996 to 2004. Mortality trends Authors: Michael Goldacre, Marie Duncan, Paula Cook-Mozaffari, Matthew Davidson, Henry McGuiness, Daniel Meddings Published by: Unit of Health-Care Epidemiology, Oxford University, and South-East England Public Health Observatory, 2006 This document provides a profile of trends in mortality for lymphoid leukaemia in England. The period covered is January 1 1996 to December 31 2004. The data are analysed from mortality files supplied to the South East England Public Health Observatories (SEPHO) by the Office for National Statistics (ONS). Mortality rates were calculated for the condition certified as the underlying cause of death and for the disease certified as any mention on the death certificates. Age-specific ...

APPLICATION FOR IMATINIB MESYLATE FOR TREATMENT OF CHRONIC MYELOID LEUKAEMIA Please send applications and prescriptions to: The Imatinib Co-ordinator PHARMAC PO Box 10-254 WELLINGTON Phone: 04 460 4990 Facsimile: 04 916 7571 Email: mary.chesterfield@ pharmac.govt.nz Details of applying practitioner Patient details Title: Mr/Mrs/Miss/Ms/Dr NHI No:. Surname:.... First names: Address:.. ..... .. Gender: Male/Female DOB:.. Phone No:... Details of patient’s General Practitioner Specialty:.. Application to be made, and subsequent prescriptions to be written, by a haematologist or an oncologist. Surname:... First names:.. NZMC registration number:.... Address:. . . Phone No:.. Facsimile No:. Email address:.. Cellphone No:. Name:...... Address:.. ..... ...

121 Leukaemia 18 18.1. INTRODUCTION AND SUMMARY Table 18.1. Summary of incidence and mortality statistics: leukaemia INCIDENT CASES DEATHS males females both sexes males females both sexes All cancers (ICD-O 2 C42.1, M-9800 to M-9941 and ICD-10 C91 to C95) 1997 cases 195 144 339 124 90 214 % of all cancers 1.8% 1.3% 1.6% 3.1% 2.5% 2.8% Incidence and mortality rates (per 100,000 persons per year) crude rate 10.8 7.8 9.3 6.9 4.9 5.9 World age-standardised rate 8.9 6.2 5.4 3.2 European age-standardised rate 12.0 7.5 7.8 4.3 cumulative risk (0-74) 0.8% 0.5% 0.5% 0.3% mortality/incidence ratio 0.636 0.625 0.631 Time trends (all cancers) 1994 cases ...

Exposure to 50-Hz Electric Field and Incidence of Leukaemia , Brain Tumors, and Other Cancers among French Electric Utility Workers Pascal Guenel, Javier Nicolau, Ellen Imbernon, Ann Chevalier, and Marcel Goldberg Recent studies on the association between exposure to 50-to 60-Hz fields and cancer carried out among electric utility workers have focused mainly on the magnetic field component of exposure. The authors have investigated tumor risks specifically associated with electric fields, as this exposure is distinct from magnetic fields. The study design is a case-control study nested within a cohort of 170,000 workers employed at Electricite de France-Gaz de France (EDF) between 1978 and 1989. All incident cases of cancer and benign tumor of the brain diagnosed in 1978 1989 among workers before the age of retirement were included. Four randomly selected controls were individually matched to each case ...

Role of maintenance therapy in Acute Myeloid Leukaemia Page 2 2 Study 1 Yves Perel, Anne Auvrignon, Thierry Leblanc, Jean-Pierre Vannier, Gerard Michel, Brigitte Nelken, Virginie Gandemer, Claudine Schmitt, Jean-Pierre Lamagnere, Lionel De Lumley, Brigitte Bader-Meunier, Gerard Couillaud, Gerard Schaison, Judith Landman-Parker, Isabelle Thuret, Jean-Hugues Dalle, Andre Baruchel, Guy Leverger for the Group LAME of the French Society of Paediatric Haematology and Immunology Impact of Addition of Maintenance Therapy to Intensive Induction and Consolidation Chemotherapy for Childhood Acute Myeloblastic Leukemia: Results of a Prospective Randomized Trial, LAME 89/91 J Clin Oncol 2002; 20: 2774-2782 Study design This was a prospective randomised multi-centre study that extended from December 1988 to June 1996 Randomisation methodology was not ...

Leukaemia Introduction Leukaemias are a group of cancers which can occur in people of any age. Leukaemias are disorders of blood cell production that result in the body accumulating abnormal blood cells. Normally the body's cells are replaced by dividing in an orderly way, allowing your body to grow and to heal after an injury. Sometimes some cells act in an abnormal way and may grow into a lump which is called a tumour. Tumours can be benign (not a cancer) or malignant (a cancer). Malignant tumours can spread to other parts of the body forming secondary cancer deposits in other areas of the body. In leukaemia it is the blood-forming cells which multiply abnormally and grow out of control. Even though leukaemias may not produce lumps they are still a type of cancer. These cancers may be either leukaemias or lymphomas . Structure and function of blood and ...

Acute Lymphoblastic Leukaemia (ALL) What is leukaemia ? Leukaemia is a cancer of cells in the bone marrow (the cells which develop into blood cells). Cancer is a disease of the cells in the body. There are many types of cancer which arise from different types of cell. What all cancers have in common is that the cancer cells are abnormal and do not respond to normal control mechanisms. Large numbers of cancer cells build up because they multiply 'out of control', or because they live much longer than normal cells, or both. With leukaemia , the cancerous cells in the bone marrow spill out into the bloodstream. There are several types of leukaemia . Most types arise from cells which normally develop into white blood cells. (The word leukaemia comes from a greek work which means 'white blood'.) If you develop leukaemia it is important to know exactly what type it is. This is because the outlook (prognosis) ...

The Leukaemia Foundation • The Leukaemia Foundation is the only national not-for-profit organisation dedicated to the care and cure of patients and families living with leukaemias, lymphomas, myeloma and related blood disorders. How these diseases change lives • Approximately 7,300 people are diagnosed with leukaemias, lymphomas and myeloma each year; the equivalent of 20 people per day. Of these, approximately 53% are diagnosed with lymphomas, 33% with leukaemias and another 14% with myeloma. • The diseases often develop with little warning, requiring immediate and intensive treatment. In acute cases, families often need to uproot their lives and relocate virtually overnight. In reality it means leaving work, school, family commitments and friends while dealing with the emotional turmoil of diagnosis and immediate treatment. • They can develop in anyone, of any age, at any time. ...

Leukaemia Foundation CommunityFundraisingGuidelines These guidelineshave been developed to assist groupsand individualswho are developing fundraisingactivitiesto benefit the Leukaemia Foundation. Theyare an essentialpart ofyourplanningand you must ensure you willbe able to comply withthese guidelinesBEFOREundertakingyourfundraisingactivity. These guidelinesare designed to protect the public,the ActivityOrganiserand the Leukaemia Foundation from unnecessaryrisk.Ifyou have anyquestions,please contact the Fundraising Coordinatorin yourLeukaemia Foundation state office. Thank you forofferingto support the Leukaemia Foundation 1. These guidelines provide the basisforafundraisingactivitytobe organisedbythe Activity Organiseron behalfofthe LeukaemiaFoundation.Ifaccepted,bysigningandreturningthe CommunityFundraisingProposalandAgreement,these FundraisingGuidelines willform the terms andconditions ofthe fund...

Leukaemias FactSheet • Leukaemia candevelopinanyone, ofanyage, atanytime. • Approximately2,370Australians arediagnosedwithleukaemias everyyear; theequivalentof6peopleeveryday. • Approximately1,363Australians willdieofleukaemias everyyear;the equivalentofalmost4peopleeveryday. • Leukaemias arethemostcommonform ofchildhoodcanceryetmorethan 90% ofAustralians diagnosedwithleukaemia areadults. • Whencomparedwithothercancers, leukaemia affects a largerproportionof childrenthanolderagegroups. • Leukaemias oftendevelopwithlittlewarning, requiringimmediateand intensivetreatment.Patients withacuteleukaemia typicallybegintreatment within24hours ofdiagnosis. • Factors thatmayaffectleukaemia‘sdevelopmentarenotclearbutmay includea person‘sgenetichistory, exposuretointenseradiationandcertain chemicalsandviruses liketheHumanT-CellLeukaemia virus. Whatareleukaemias? ...

Oct 05 This information booklet is produced by the Leukaemia Foundation and is one in a series on blood cancers and related disorders. Some booklets are also available in other languages. Copies of this booklet and the other booklets can be obtained from the Leukaemia Foundation in your state by contacting us on Freecall: 1800 620 420 Email: info@ leukaemia .com Website: www. leukaemia .com The Leukaemia Foundation is a non-profit organisation that depends on donations and support from the community. Please support our work by calling 1800 620 420 or by mailing your donation to: The Leukaemia Foundation GPO Box 9954 in your capital city Understanding Acute Myeloid Leukaemia (AML) A guide for patients, carers and families Page 2 Oct 05 This information booklet is produced by the Leukaemia ...

Page 1 of 4 of Instrument No.84 of 2001 Instrument No.84 of 2001 Revocation and Determination of Statement of Principles concerning ACUTE LYMPHOID LEUKAEMIA ICD-10-AM CODES: C91.0, C91.5 Veterans’ Entitlements Act 1986 1. The Repatriation Medical Authority under subsection 196B(3) of the Veterans’ Entitlements Act 1986 (the Act): (a) revokes Instrument No.78 of 1995; and (b) determines in its place the following Statement of Principles. Kind of injury, disease or death 2. (a) This Statement of Principles is about acute lymphoid leukaemia and death from acute lymphoid leukaemia . (b) For the purposes of this Statement of Principles, “acute lymphoid leukaemia ” means a malignant disease of the early precursor cells of the B cell and T cell lymphocytic lineages, attracting ICD-10-AM code ...

Page 1 of 4 of Instrument No. 9 of 2005 Instrument No. 9 of 2005 Revocation and Determination of Statement of Principles concerning CHRONIC LYMPHOID LEUKAEMIA for the purposes of the Veterans’ Entitlements Act 1986 and Military Rehabilitation and Compensation Act 2004 1. The Repatriation Medical Authority under subsection 196B(2) and (8) of the Veterans’ Entitlements Act 1986 (the VEA): (a) revokes Instrument No. 67 of 2001, as amended by No. 59 of 2003; and (b) determines in their place the following Statement of Principles. Kind of injury, disease or death 2. (a) This Statement of Principles is about chronic lymphoid leukaemia and death from chronic lymphoid leukaemia . (b) For the purposes of this Statement of Principles, “chronic lymphoid leukaemia ” means an indolent ...

Page 1 of 4 of Instrument No.15 of 2003 Instrument No.15 of 2003 Revocation and Determination of Statement of Principles concerning CHRONIC MYELOID LEUKAEMIA Veterans’ Entitlements Act 1986 1. The Repatriation Medical Authority under subsection 196B(2) of the Veterans’ Entitlements Act 1986 (the Act): (a) revokes Instrument No.7 of 1997; and (b) determines in its place the following Statement of Principles. Kind of injury, disease or death 2. (a) This Statement of Principles is about chronic myeloid leukaemia and death from chronic myeloid leukaemia . (b) For the purposes of this Statement of Principles, “chronic myeloid leukaemia ” means a haematological neoplasm characterised by the clonal proliferation and accumulation of mature myeloid cells and their progenitors in the peripheral ...

Page 1 of 4 of Instrument No.83 of 2001 Instrument No.83 of 2001 Revocation and Determination of Statement of Principles concerning ACUTE LYMPHOID LEUKAEMIA ICD-10-AM CODES: C91.0, C91.5 Veterans’ Entitlements Act 1986 1. The Repatriation Medical Authority under subsection 196B(2) of the Veterans’ Entitlements Act 1986 (the Act): (a) revokes Instrument No.77 of 1995; and (b) determines in its place the following Statement of Principles. Kind of injury, disease or death 2. (a) This Statement of Principles is about acute lymphoid leukaemia and death from acute lymphoid leukaemia . (b) For the purposes of this Statement of Principles, “acute lymphoid leukaemia ” means a malignant disease of the early precursor cells of the B cell and T cell lymphocytic lineages, attracting ICD-10-AM code ...

Page 1 of 4 of Instrument No. 10 of 2005 Instrument No. 10 of 2005 Revocation and Determination of Statement of Principles concerning CHRONIC LYMPHOID LEUKAEMIA for the purposes of the Veterans’ Entitlements Act 1986 and Military Rehabilitation and Compensation Act 2004 1. The Repatriation Medical Authority under subsection 196B(3) and (8) of the Veterans’ Entitlements Act 1986 (the VEA): (a) revokes Instrument No. 68 of 2001; and (b) determines in its place the following Statement of Principles. Kind of injury, disease or death 2. (a) This Statement of Principles is about chronic lymphoid leukaemia and death from chronic lymphoid leukaemia . (b) For the purposes of this Statement of Principles, “chronic lymphoid leukaemia ” means an indolent malignant neoplasm of B-lymphocytes ...

THE BUD FLANAGAN LEUKAEMIA FUND Mrs. S. Clark General Secretary Printing House 66 Lower Road Harrow HA2 0DH GIFT AID DECLARATION BY COMPLETING THIS FORM YOU CAN INCREASE YOUR DONATION BY AN AMOUNT EQUAL TO THE BASIC RATE OF INCOME TAX TITLE . FORENAME: .. SURNAME: .. ADDRESS: . . . POSTCODE: .. I would like the Bud Flanagan Leukaemia Fund to benefit by reclaiming tax on all payments I have made since 6 th April 2000 and all payments I make hereafter to the Fund Signature: . Date: Please turn over for explanatory notes Registered Charity No. 1092540 Page 2 Gift Aid Declaration notes:- • You can cancel this declaration at any time by notifying the Fund • You must pay an amount of income tax or capital gains ...

Magnetic field exposure and long-term survival among children with leukaemia DE Foliart * ,1 , BH Pollock 2 , G Mezei 3 , R Iriye 4 , JM Silva 4 , KL Ebi 5 , L Kheifets 6 , MP Link 7 and R Kavet 3 1 Public Health Institute, 555 12th St, Oakland, CA 94607, USA; 2 Center for Epidemiology and Biostatistics, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA; 3 Electric Power Research Institute (EPRI), 3412 Hillview Avenue, Palo Alto, CA 94304, USA; 4 Enertech Consultants, 300 Orchard City Drive, Suite 132, Campbell, CA 95008, USA; 5 Exponent Health Sciences Group, 1800 Diagonal Road, Suite 300, Alexandria, VA 22314, USA; ...

Mortality from Leukaemia (SMR with 95% CI) 2002-2004, All Ages by Strategic Health Authority (SHA) Notes Mortality from leukaemia (ICD10 C91-C95) Indirectly standardised ratios (SMR) All ages 2002-04 (Pooled) England 2002-04 = 100 (Standard rates are England annual age-specific rates 2002-04) Data are based on the original underlying cause of death. Data are based on the latest revisions of ONS population estimates for the respective years, current as of the 1st September 2005. Highlights Male and female mortality from leukaemia in Bedfordshire and Hertfordshire SHA was not significantly different from England or the neighbouring SHA's. For More Information Please Contact David Edwards, Public Health Intelligence Epidemiologist (david.edwards@phi-bedsherts.nhs.uk) Page 2 Source: National Statistics, Compendium of Clinical and Health Indicators (Release ...

Seventeenth Annual Fanconi Anemia Research Fund Scientific Symposium Poster Presentation 97 No Evidence of Significant FANCF Methylation in Sporadic Acute Childhood Leukaemia S. Meyer 1 , D.J. White 2 , L. Barber 2 , A.M Will 1 , T.O.B. Eden 1 , A. Medhurst 3 , F. Chen 3 , J.P. De Winter 3 , H. Joenje 3 , A. Simps 4 , R. Brown 4 , and G. Strathdee 4 1 Department of Paediatric Oncology, Central Manchester and Manchester Children’s Hospital NHS Trust; 2 Cancer-Immunogenetics Laboratory, University of Manchester, Manchester, UK; 3 Department of Clinical Genetics and Human Genetics, Vrije University, Amsterdam, The Netherlands; 4 ...

doi:10.1136/oem.2005.023036 2006;63;131-134 Occup. Environ. Med. Sommelet, D Hémon and J Clavel F Menegaux, A Baruchel, Y Bertrand, B Lescoeur, G Leverger, B Nelken, D childhood acute leukaemia Household exposure to pesticides and risk of http://oem.bmjjournals.com/cgi/content/full/63/2/131 Updated information and services can be found at: These include: References http://oem.bmjjournals.com/cgi/content/full/63/2/131#otherarticles 1 online articles that cite this article can be accessed at: http://oem.bmjjournals.com/cgi/content/full/63/2/131#BIBL This article cites 17 articles, 4 of which can be accessed free at: Rapid responses http://oem.bmjjournals.com/cgi/eletter-submit/63/2/131 You can respond to this article at: service Email alerting top right corner of the article Receive ...

CHILDREN with LEUKAEMIA Terms and conditions of funding This Agreement dated [insert date] contains the terms and conditions that apply to the award of a grant (the “Grant ”) by CHILDREN with LEUKAEMIA of 51 Great Ormond Street, London WC1N 3JQ, registered charity no 298405 (the “ Charity ”). They cover the contractual arrangements between the Charity and the Host Institution (as defined below) at which the research described in the Proposal (as defined below) (the “ Research ”) is to be carried out and also the working arrangements between the Charity, the Grant Holder and the Host Institution (as defined below). These terms and conditions must be signed by way of acceptance by the Grant Holder, and by two duly authorised officers (normally the Head of Department and the Finance Officer) on behalf of the Host Institution. Additional terms and conditions which may apply to specific awards will ...

Guidelines on the diagnosis and management of chronic lymphocytic leukaemia Methods The purpose of this guideline is to provide a rational approach to the diagnosis and management of patients with chronic lymphocytic leukaemia (CLL). This guideline has been compiled by the Guidelines Working Group of the UK CLL Forum on behalf of the British Committee for Standards in Haematology (BCSH). Recommendations are based on a review of the literature using Medline/Pubmed searches under the heading, CLL, up to October 2003 and data presented at the American Society of Hematology in 2003 and at the 10th International Workshop on CLL in 2003. The results of meta-analyses and phase 3 studies that have been published or presented in abstract form are included. Treatment recommendations were influenced by current and proposed clinical trials in the UK and by guidance from The National Institute ...

95 RECENT ADVANCES IN THE THERAPY OF ACUTE LEUKAEMIA * HAU C. KWAAN, M.D., F.R.C.P. (EDIN.), F.A.C.P. From the Department of Medicine, Northwestern University Medical School, and the Haematology Section, Veterans Administration Research Hospital, Chicago, Illinois, U.S.A. In recent years, significant advances have been made in the understanding of malignant diseases; leading to significant improvements in the survival rate. Among the various neoplastic conditions the improvements in the morbidity and mortality figures in acute leukaemia show perhaps the best results. While the diagnosis of acute leukaemia carried with it grave prognostic implications as recently as ten years ago, it is possible today to speak of a "cure” with chemo- therapy. I would like to discuss the following key factors that are contributing ...

The Journal Protocol Reviews eResearch Archive Info for Authors Profile Help Feedback The Journal Current Issue Supplements Back Issues Contents in full Talking points Original research News Editorial and review Correspondence Clinical picture Dissecting room Search Journal Subscribe E-Toc Log Out Jobs Awards and Announcements Conferences Press Services General Info Free Sample Contact Us Home The Journal Back Issues Original research Volume 363, Number 9403 10 January 2004 Jenny A Orchard, Rachel E Ibbotson, Zadie Davis, Adrian Wiestner, Andreas Rosenwald, Peter W Thomas, Terry J Hamblin, Louis M Staudt, David G Oscier Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK (J A Orchard FRCPath, R E Ibbotson PhD, Z Davis BSc, T ...

Mortality from Leukaemia (SMR) 2001-2003, All Ages Notes Mortality from leukaemia (ICD10 C91-C95) Indirectly standardised ratios (SMR) All ages 2001-03 (Pooled) England 2001-03 = 100 (Standard rates are England annual age-specific rates 2001-03) Data are based on the original underlying cause of death. Data are based on ONS population estimates (February 2005 release). Highlights At PCT level there was no significant difference in Leukaemia mortality from England. St Albans & Harpenden had the lowest ratio of Leukaemia mortality in Bedfordshire and Hertfordshire SHA, while Watford & Three Rivers PCT had the highest ratio of Leukaemia mortality in Bedfordshire and Hertfordshire SHA. For More Information Please Contact David Edwards, Public Health Intelligence Epidemiologist (david.edwards@phi-bedsherts.nhs.uk) Page 2 Source: National Statistics, ...

Page 2 Myeloid leukaemia cough in England 1998/9 to 2002/3. A geographical profile of hospital admissions. Authors: Michael Goldacre, David Yeates, Leicester Gill, Henry McGuinness, Daniel Meddings Published by: Unit of Health-Care Epidemiology, Oxford University, and South East England Public Health Observatory, 2005 This document provides a geographical profile of hospital admission for myeloid leukaemia in England. The geographical areas covered are the standard local authority areas of England. The period covered is April 1 1998 to March 31 2003. The data are from Hospital Episode Statistics (HES). HES includes data on all NHS hospital admissions (including admissions for day case care). This analysis includes HES data about men and women of all ages. The maps show: (a) The spell-based admission rates per 100,000 resident population for each local ...

Leukaemia Busters The Children’s Leukaemia Research Charity 2006 A Purbeck Odyssey Walking for Their Lives To boldly tread where only some men, women and children have been before Corfe Castle and beyond Sunday 25 June Picture by Andrew P M Wright Registration form part 2 Registration fees: Qty sub-total ? Castle Walk .Adults at £6.00 each . .Young adults (12–16 years) at £3.00 each . .Children (under 12 years) at £2.00 each . ? Whale Walk (Fee includes train fare) .Adults at £10.00 each .. .Young adults (12–16 years) at £6.00 each . .Children (under 12 years) at £5.00 each . ? Dolphin Walk (Fee includes train fare) .Adults at £10.00 each .. .Young adults (12–16 years) at £6.00 each . ? Purbeck Voyage .Adults at £6.00 each . .Young adults (12–16 years) ...

HK J Paediatr (new series) 2006; 11 :69-72 Cerebral Infarction in Childhood Acute Lymphoblastic Leukaemia Treated with Low Dose E. coli Asparaginase LM P ESQUERA -L EPATAN , GCF C HAN , C L AM , MHK H O , TL L EE , AKS C HIANG , SY H A , YL L AU Section of Pediatric Hematology and Oncology, Santo Tomas University Hospital, Manila, Philippines LM P ESQUERA -L EPATAN MD Department of Paediatrics & Adolescent Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong, China GCF C HAN MD, FHKAM(Paed), FRCPCH(UK) MHK H O ...

Institute of Child Health & Great Ormond Street Hospital Molecular Basis of Childhood Leukaemia Thursday 23 – Friday 24 March 2006 Provisional Programme Thursday 23 rd March 2006 09.45 Introduction Hugh Brady, Institute of Child Health The MLL Gene and Leukaemia 10.00 MLL fusion genes: what do they tell us about acute leukaemia ? Eric So, Institute of Cancer Research, London 10.40.1 MLL fusions in leukaemia : different proteins, one function? Robert Slany, University of Erlangen 11.20 T E A / C O F F E E 11.50 Pathological mechanisms in t(4;11) leukaemia : new insights and perspectives Rolf Marschalek, University of Frankfurt 12.30 MLL - Leukaemia and Epigenetices Jay Hess, University of Michigam 13.10.1 L U N C H Page 2 Acute ...